Article
Rheumatology
Gregory McDermott, Ritu Gill, Staci Gagne, Suzanne Byrne, Weixing Huang, Xiaosong Wang, Lauren C. Prisco, Alessandra Zaccardelli, Lily W. Martin, Lucy Masto, Vanessa L. Kronzer, Nancy Shadick, Paul F. Dellaripa, Tracy J. Doyle, Jeffrey A. Sparks
Summary: The study investigates the demographic, lifestyle, and serologic risk factors associated with isolated rheumatoid arthritis (RA)-associated bronchiectasis (RA-BR) that is not caused by interstitial lung disease (ILD). The findings suggest that seropositivity, older age at RA diagnosis, and lower BMI at RA onset are associated with isolated bronchiectasis in RA that is not a result of ILD.
JOURNAL OF RHEUMATOLOGY
(2022)
Article
Rheumatology
Krystel Aouad, Philippe Gaudin, Olivier Vittecoq, Jacques Morel, Jean-Marie Berthelot, Eric Senbel, Thierry Schaeverbeke, Frederic Liote, Rene-Marc Flipo, Alexandrine Pinta, Francis Guillemin, Bruno Fautrel
Summary: The FLARE-RA questionnaire aims to identify flare in rheumatoid arthritis patients, with a proposed cut-off score of 2.3 for acceptable situation based on patient satisfaction. The correlation between FLARE-RA score and DAS28(ESR) AUC was moderate, indicating a difference between the assessments.
Article
Medicine, Research & Experimental
Patricia Ruiz-Limon, Natalia Mena-Vazquez, Isabel Moreno-Indias, Sara Manrique-Arija, Jose Manuel Lisbona-Montanez, Laura Cano-Garcia, Francisco J. Tinahones, Antonio Fernandez-Nebro
Summary: This study analyzed the gut microbiota of patients with rheumatoid arthritis (RA) according to disease activity. The results showed differences in gut microbiota between patients with moderate/high activity RA, patients with remission/low activity, and controls. The genus Collinsella, age, obesity, and physical function were found to be associated with cumulative inflammatory burden in RA.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Rheumatology
Farzin Khosrow-Khavar, Seoyoung C. Kim, Hemin Lee, Su Been Lee, Rishi J. Desai
Summary: The study did not find evidence of increased cardiovascular risk with tofacitinib in patients with RA in a real-world setting. However, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Immunology
Yuan Qu, Yang Fu, Yuan Liu, Chuanguo Liu, Bing Xu, Qian Zhang, Ping Jiang
Summary: Transient receptor potential cation channel subfamily V member 1 (TRPV1) has been found to play a role in immune regulation and its dysregulation affects the development of rheumatoid arthritis. Understanding the mechanism of TRPV1 can lead to the design of new drugs and improved treatment of RA.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Rheumatology
Heidi J. Siddle, Lara S. Chapman, Kulveer Mankia, Codruta Zabalan, Marios Kouloumas, Karim Raza, Marie Falahee, Joel Kerry, Andreas Kerschbaumer, Daniel Aletaha, Paul Emery, Suzanne H. Richards
Summary: The study identified the importance of understanding the risk, engaging in preventive interventions, and undergoing predictive testing for individuals at-risk of rheumatoid arthritis. However, barriers to engagement exist, intensified by the burden of uncertainty. It is urgently needed to identify optimal approaches for presenting risk information to support decision-making for individuals at-risk of RA.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
R. Raadsen, R. Agca, M. Boers, V. P. van Halm, M. J. L. Peters, Y. Smulders, J. W. J. Beulens, M. T. Blom, C. D. A. Stehouwer, A. E. Voskuyl, W. F. Lems, M. T. Nurmohamed
Summary: This study investigated the cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients over a 20-year follow-up, with a focus on patients without prevalent CVD. The results showed that the increased risk of CVD in RA patients without prevalent CVD is mainly due to the presence of traditional risk factors rather than RA itself.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2023)
Review
Medicine, General & Internal
Bas Dijkshoorn, Reinder Raadsen, Michael T. Nurmohamed
Summary: RA patients have a 1.5 times higher risk of developing cardiovascular diseases compared to the general population. This is partly due to systemic inflammation causing increased atherogenesis, and an increased prevalence of traditional cardiovascular risk factors.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Paul Studenic, Aase Hensvold, Arnd Kleyer, Annette van der Helm-van Mil, Arthur G. Pratt, Daniela Sieghart, Gerhard Kroenke, Ruth Williams, Savia de Souza, Susanne Karlfeldt, Martina Johannesson, Niels Steen Krogh, Lars Klareskog, Anca I. Catrina
Summary: This article introduces different initiatives for the management of individuals at high risk of rheumatoid arthritis and successfully establishes a European registry for at-risk individuals. Similarities and differences between research institutions and cohorts from different countries are outlined in order to facilitate data harmonization. The article emphasizes the importance of collaborative research in addressing this issue from different perspectives.
FRONTIERS IN MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Daniela Maria Tanase, Evelina Maria Gosav, Daniela Petrov, Dan-Stefan Teodorescu, Oana Nicoleta Buliga-Finis, Anca Ouatu, Ionut Tudorancea, Elena Rezus, Ciprian Rezus
Summary: Rheumatoid Arthritis (RA) is a common and impactful rheumatologic chronic autoimmune disease worldwide. The exact cause of RA remains unclear, but it is believed to be a combination of genetic susceptibility and environmental triggers. Systemic inflammation associated with RA increases the risk of comorbidities such as cardiovascular disease. Non-coding RNAs, particularly microRNAs, play a key role in the pathogenesis of RA and its cardiovascular consequences, and have potential as biomarkers and therapeutic targets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Rheumatology
Cynthia S. Crowson, Tina M. Gunderson, Hayley J. Dykhoff, Elena Myasoedova, Elizabeth J. Atkinson, Vanessa L. Kronzer, Caitrin M. Coffey, John M. Davis
Summary: This study comprehensively assessed the burden of multimorbidity in patients with rheumatoid arthritis (RA) and found that RA patients have a higher prevalence of multimorbidity compared to non-RA patients. Interstitial lung disease, fibromyalgia, osteoarthritis, and osteoporosis were common morbidities in RA patients.
Article
Rheumatology
Giovanni Adami, Angelo Fassio, Maurizio Rossini, Davide Bertelle, Francesca Pistillo, Camilla Benini, Ombretta Viapiana, Davide Gatti
Summary: Reducing glucocorticoid doses in rheumatoid arthritis patients can effectively decrease the risk of disease flare-ups. However, choosing the right tapering strategy remains challenging. The study found that tapering glucocorticoids to doses of 2.5 mg/day or below was associated with a higher risk of flare, suggesting the need for better tapering strategies to reduce the risk of recurrence in rheumatoid arthritis patients on biological disease-modifying antirheumatic drugs.
Editorial Material
Rheumatology
Camilla R. L. Machado, Gary S. Firestein
Summary: Rheumatoid arthritis synovium contains fibroblast-like synoviocytes that are phenotypically and functionally heterogeneous. Advanced analyses have identified at least four distinct cell states, which are determined by the cells' location in the synovium, epigenetic imprinting, and the influence of microenvironment mediators.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Immunology
Ennio Giulio Favalli, Gilberto Cincinelli, Sabino Germinario, Raffaele Di Taranto, Francesco Orsini, Gabriella Maioli, Martina Biggioggero, Matteo Ferrito, Roberto Caporali
Summary: This study evaluated the impact of EMA recommendations on the prescription of JAK inhibitors (JAKis) and the use of the Expanded Risk Score in RA (ERS-RA) to quantify the risk of major adverse cardiac events (MACE) in patients with rheumatoid arthritis (RA). A large proportion of RA patients were classified as ineligible for JAKis according to EMA criteria, with increased MACE risk being the most common reason. The use of ERS-RA method significantly reduced the rate of patients with increased cardiovascular risk.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Rheumatology
Anthony James Ocon, George Reed, Dimitrios A. Pappas, Jeffrey R. Curtis, Joel M. Kremer
Summary: The study found that initiating glucocorticoids in steroid-naive RA patients is associated with an increased risk of cardiovascular events, especially at daily doses of >= 5mg, cumulative doses exceeding 1100mg, and durations longer than 81 days. No increased risk was found at lower doses or shorter durations.
ANNALS OF THE RHEUMATIC DISEASES
(2021)